Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 212

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 212
---
     | $              | [● | ] |     |                  | [● | ] |
| Proceeds,                                                                                        
 before expenses, to us                                                                           |     | $        | [● | ] |     | $              | [● | ] |     |                  | [● | ] |

| (1) | We have agreed to pay the Representative a discount equal to                                                                                      
 seven percent (6.0%) of the gross proceeds of this offering and each closing of the over-allotment option (if any) sourced by the Representative. |

| (2) | We also agreed to pay the Representative                                                                            
 a non-accountable expense allowance in the amount equal to one percent (1%) of the gross proceeds of this offering. |

<div align='center'>123</div>

We agreed to reimburse the Representative for
reasonable out-of-pocket accountable expenses of no more than US$250,000, regardless of whether this Offering is closed.

We advanced an expense deposit of US$70,000 to
the Representative after the execution of the letter of intent between us and the Representative, US$80,000 at the first public filing
of this registration statement and US$100,000 upon the effectiveness of this registration statement for the Representative’s anticipated
out-of-pocket expenses. In the event the IPO is terminated or is not successfully closed, any unused portion of the advanced payment will
be returned to us to the extent not actually incurred in accordance with FINRA Rule 5110(g)(4)(A).

We also agreed to pay to the Representative non-accountable expenses
equal to 1.0% of the gross proceeds raised in this Offering.

We estimate that the total expenses payable by us in connection with this Offering, other than the underwriting fees, commissions and the Representative’s accountable expense and non-accountable expense, will be approximately US$[●].

Lock-Up Agreements

We agreed that, subject to certain exceptions
set forth in the underwriting agreement/lock-up agreements, we will not, without the prior written consent of the Representative, from
the date of execution of the underwriting agreement and continuing for six (6) months from the date of this Offering, (i) offer,
sell, or otherwise transfer or dispose of, directly or indirectly, any Class A Ordinary Shares of the Company or any securities convertible
into or exercisable or exchangeable for Class A Ordinary Shares of the Company; or (ii) file or caused to be filed any registration statement
with the SEC relating to the